Eventide Asset Management, LLC Intercept Pharmaceuticals, Inc. Transaction History

Eventide Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$12.53 - $21.71 $3.75 Million - $6.49 Million	-298,967 Reduced 37.37%	501,033 $6.73 Million
Q1 2022 May 16, 2022	BUY	$13.37 - $17.79 $6.32 Million - $8.41 Million	472,556 Added 144.32%	800,000 $13 Million
Q4 2021 Feb 14, 2022	BUY	$14.28 - $19.53 $4.68 Million - $6.39 Million	327,444 New	327,444 $5.33 Million
Q1 2020 May 15, 2020	SELL	$48.35 - $118.68 $4.84 Million - $11.9 Million	-100,000 Closed	0 $0
Q4 2019 Jan 29, 2020	BUY	$57.36 - $124.1 $5.74 Million - $12.4 Million	100,000 New	100,000 $12.4 Million
Q2 2019 Aug 14, 2019	SELL	$77.77 - $120.68 $15.9 Million - $24.7 Million	-205,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $3.4 Million - $4.47 Million	37,000 Added 22.02%	205,000 $22.9 Million
Q4 2018 Feb 14, 2019	BUY	$85.79 - $126.46 $14.4 Million - $21.2 Million	168,000 New	168,000 $16.9 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.